Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

MEC Basic

Speciality

Author / Speaker

Title

Type of Media

Events

Search Everything

«
1
2
3
4
…
62
»

Moving the Bar Beyond PACIFIC. What is the Best Consolidation Therapy for People with Actionable and Non-Actionable Genes?

Moving the Bar Beyond PACIFIC. What is the Best Consolidation Therapy for People with Actionable and Non-Actionable Genes?

Tom Stinchcombe, MD

Combining Immunotherapy with Radiation for LA-NSCLC

Combining Immunotherapy with Radiation for LA-NSCLC

Megan Daly, MD

Assessing Resectability in Stage III NSCLC

Assessing Resectability in Stage III NSCLC

Linda Martin, MD

Update Progress in Targeted Therapies for Early-Stage NSCLC

Update Progress in Targeted Therapies for Early-Stage NSCLC

Lyudmila Bazhenova, MD

Which Patients Need Adjuvant Therapy?

Which Patients Need Adjuvant Therapy?

Karen Reckamp, MD

Debate- Is Perioperative Immunotherapy the New Standard of Care? No.

Debate- Is Perioperative Immunotherapy the New Standard of Care? No.

Hossein Borghaei, DO

Debate- Is Perioperative Immunotherapy the New Standard of Care? Yes.

Debate- Is Perioperative Immunotherapy the New Standard of Care? Yes.

Rachel E. Sanborn, MD

Perioperative Chemo/Immunotherapy and Surgical Outcomes

Perioperative Chemo/Immunotherapy and Surgical Outcomes

Jay M. Lee, MD

What is the Best Way to Assess Response to Therapy? Is Complete Pathologic Response the Best Surrogate?

What is the Best Way to Assess Response to Therapy? Is Complete Pathologic Response the Best Surrogate?

Lynette M. Sholl, MD

Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms

Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms

Matthew Smeltzer, PhD

Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?

Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?

Gerard Silvestri, MD

Existing and Emerging Tests for Cancer Interception: How Low do We have to Go (with the LOD)? Does Methylation Help?

Existing and Emerging Tests for Cancer Interception: How Low do We have to Go (with the LOD)? Does Methylation Help?

Triparna Sen, PhD

Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes?

Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes?

Claudia I. Henschke, MD, PhD

B-Cell NHL (Aggressive)-Relapsed (CAR T versus Bispecifics?)

B-Cell NHL (Aggressive)-Relapsed (CAR T versus Bispecifics?)

Julio C. Chavez, MD, MS

T-Cell NHL- Novel therapies

T-Cell NHL- Novel therapies

Steve Horwitz, MD

Myelodysplasia

Namrata S. Chandhok, MD

Acute Myeloid Leukemia

Acute Myeloid Leukemia

Talha Badar, MBBS, MD

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Javier Pinilla-Ibarz, MD, PhD

$Updates in relapsed/refractory Multiple Myeloma$

Updates in relapsed/refractory Multiple Myeloma

Sagar Lonial, MD, FACP

Advances in Multiple Myeloma in Front Line Setting

Advances in Multiple Myeloma in Front Line Setting

Ivan M. Borrello, MD

Updates on SCLC and Mesothelioma

Updates on SCLC and Mesothelioma

Triparna Sen, PhD

ADC in NSCLC: Too Much Hope?

ADC in NSCLC: Too Much Hope?

Noman Ashraf, MD

Updated Management on Advanced NSCLC Driver Mutant Tumors

Updated Management on Advanced NSCLC Driver Mutant Tumors

Edgardo S. Santos, MD, FACP, FASCO

Stage III Unresectable NSCLC: Any Progress Beyond PACIFIC?

Stage III Unresectable NSCLC: Any Progress Beyond PACIFIC?

Jorge E. Gomez, MD

Utilization of Immunotherapy in the Perioperative Setting

Utilization of Immunotherapy in the Perioperative Setting

Luis E. Raez, MD, FACP, FASCO

Understanding Germline Testing: When? Who? And What is Next?

Understanding Germline Testing: When? Who? And What is Next?

Banu Arun, MD, FASCO

Moving ctDNA Utilization Beyond Predictive Biomarkers: The Next Frontier

Moving ctDNA Utilization Beyond Predictive Biomarkers: The Next Frontier

Christian Rolfo, MD, PhD, MBA, Dr.hc

Advances in Castration-Resistant Prostate Cancer

Advances in Castration-Resistant Prostate Cancer

Mayer Fishman, MD, PhD

Updates in the Management of Kidney and Bladder Cancer

Updates in the Management of Kidney and Bladder Cancer

Pedro Barata, MD, MSc, FACP|

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Virginia Borges, MD, MMSc

Displaying 31 - 60 of 1,833

Post navigation

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Useful Links

Library
Live Events

Categories

MEC Basic
MEC Plus
Purchased

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok